| COPD and the response of the lung to tobacco smoke exposure. | |
| | |
MedLine Citation:
|
PMID: 20382250 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of death in the western world and increasing in prevalence in developing countries. COPD is characterised by irreversible airflow obstruction, loss of lung tissue, reduced quality of life and high rates of mortality. The major cause of COPD is tobacco smoke. The changes in the innate immune system directed by tobacco smoke exposure lead to a pronounced and chronic inflammation in the lung. This in turn leads to other pathological changes including remodelling and destruction of lung tissue. Tobacco smoke exposure also leads to infection of the lung by bacteria and viruses. These, bacteria, viruses and co-infection are key triggers of acute worsening's of COPD termed exacerbations. COPD exacerbations are an additional major factor in the morbidity and mortality within COPD and are also the major healthcare costs associated with the disease. Within this review we discuss the response of the immune system to cigarette smoke exposure and inappropriate harmful responses. Successful treatment strategies will need to balance the positive effects of reducing inflammatory aspects of the disease whilst retaining some of the needed immune responses triggered by tobacco smoke exposure. |
| | |
Authors:
|
John D Taylor |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-04-09 |
Journal Detail:
|
Title: Pulmonary pharmacology & therapeutics Volume: 23 ISSN: 1522-9629 ISO Abbreviation: Pulm Pharmacol Ther Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-08-11 Completed Date: 2010-12-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9715279 Medline TA: Pulm Pharmacol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 376-83 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Integrative Pharmacology, Biosciences R&D Lung, Respiratory & Inflammation Research Area, AstraZeneca, Lund, Sweden. john.d.taylor@astrazeneca.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Humans Lung / physiopathology* Pulmonary Disease, Chronic Obstructive / etiology*, physiopathology Risk Factors Smoking / adverse effects* Tobacco Smoke Pollution / adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Tobacco Smoke Pollution |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A laccase exclusively expressed by Metarhizium anisopliae during isotropic growth is involved in pig...
Next Document: Cave colonization without fasting capacities: an example with the fish Astyanax fasciatus mexicanus.